Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewXMD 8-87 is a potent Ack1/TNK2 inhibitor (IC50 = 38 and 113 nM in Ba/F3 cell lines containing leukemia-associated D163E and R806Q mutations respectively). Blocks phosphorylation of TNK2 receptors containing solid-tumor type truncation mutations.
Sold under license from Dana-Farber Cancer Institute.
分子量 | 445.52 |
公式 | C24H27N7O2 |
储存 | Store at RT |
纯度 | ≥98% (HPLC) |
CAS Number | 1234480-46-6 |
PubChem ID | 53322923 |
InChI Key | LGLHCXISMKHLIK-UHFFFAOYSA-N |
Smiles | COC1=C(C=CC(N2CCN(CC2)C)=C1)NC3=NC=C4NC(C5=CC=CC=C5N(C4=N3)C)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Maxson et al (2015) Identification and characterization of tyrosine kinase nonreceptor 2 mutations in leukemia through integration of kinase inhibitor screening and genomic analysis. Cancer.Res. 76 127 PMID: 26677978
Maxson et al (2014) Development and repurposing of small-molecule kinase inhibitors to target novel leukemogenic TNK2 mutations Blood 124 435
关键词: XMD 8-87, XMD 8-87 supplier, XMD8-87, Inhibitors, inhibits, Ack1, TNK2, Ba/F3, leukemia, D163E, R806Q, phosphorylation, tyrosine, kinase, 2, 6061, Tocris Bioscience
目前没有该产品的评论。 Be the first to review XMD 8-87 and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.